Effect of capmatinib on the pharmacokinetics of substrates of CYP3A (midazolam) and CYP1A2 (caffeine) in patients with MET-dysregulated solid tumours.

British journal of clinical pharmacology2023Chen X, Isambert N, López-López R, et al.

Study designOther primary literature

SubjectHuman

Abstract

cc by 以外（cc by-nc / cc by-nc-nd / NONE 等）は抄録を再掲しない。DOI/PMID へのリンクのみ表示する。

MeSH

Area Under CurveBenzamidesCaffeineCytochrome P-450 CYP1A2Cytochrome P-450 CYP3ACytochrome P-450 Enzyme SystemDrug InteractionsHumansImidazolesMidazolamTriazines

DOI 10.1111/bcp.15544

PMID 36131603

View source →